In addition to T790M and c-MET amplification, Axl kinase is found to be upregulated in humans with acquired resistance to EGFR-TKI, and the involvement of Axl kinase in acquired resistance of NSCLC to RGFR-TKIs gefitinib or erlotinib has been reported [38, 58, 68]. Here, MET is linked to non-small cell lung carcinoma.